Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Brain-Targeting drug ease Parkinson's dementia symptoms?

NCT ID NCT04470037

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested a drug called DAAOI-P in 61 people with Parkinson's disease who also have dementia. The goal was to see if the drug could improve walking, reduce falls, and ease neuropsychiatric symptoms. Participants received either DAAOI-P or a placebo pill for a period, and changes were measured using standard rating scales.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DAAOI-P (a drug that modulates NMDA receptors)
What this could lead to
If successful, DAAOI-P could offer a new treatment option to improve movement and behavioral symptoms in people with Parkinson's dementia.
What could go wrong
This is a small Phase 2 trial with only 61 participants, so results may not apply to everyone. The drug may not show clear benefits or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

61 people

The number who actually took part.

Started

Apr 2016

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PD-D will be diagnosed according to the criteria proposed by Movement Disorder Society task force statement. (Emre et al. 2007) . The following wordings are modified from the task force statement. I. Core features 1. Diagnosis of PD according to Queen Square Brain Bank criteria 2. A dementia syndrome with insidious onset and slow progression, developing within the context of established PD and diagnosed by history, clinical, and mental examination, defined as: * Impairment in more than one cognitive domain * Representing a decline from premorbid level * Deficits severe enough to impair daily life, independent of the impairment ascribable to motor or autonomic symptoms * MMSE score between 10-26. II. Associated clinical features 1. Cognitive features: Impaired attention, executive functions, visuo-spatial functions or memory. Core functions of language are largely preserved. 2. Behavioral features: * Apathy * Changes in personality and mood * Hallucination• Delusions * Excessive daytime sleepiness III. Features which do not exclude PD-D, but make the diagnosis uncertain * Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of dementia. * Time interval between the development of motor and cognitive symptoms is uncertain IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when present make it impossible to reliably diagnose PD-D * Cognitive and behavioral symptoms appearing solely in the context of other conditions such as: 1. Acute confusion due to systemic illnesses or drug intoxication. 2. Major depression * Features compatible with "Probable Vascular dementia" criteria according to NINDS-AIREN Criteria for the diagnosis of probable and possible PD-D \[Probable PD-D\] Both core features must be present. In associated clinical features, typical profile of cognitive deficits should be present in at least 2 of the 4 core cognitive domains. The presence of at least one behavioral symptom supports the diagnosis of probable PD-D. None of group III and IV features is present. \[Possible PD-D\] Both core features must be present. In associated clinical features, the cognitive impairment is atypical in one or more domains. The behavioral symptoms are not necessary to be present. One or more of the group III features may be present. No group IV feature is allowed to be present. Exclusion Criteria: 1. Patients with uncontrollable malignancy, severe heart failure, uremia under hemodialysis, or decompensated liver cirrhosis. 2. Patients taking anticholinergics within 30 days of recruitment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Psychiatry, China Medical University Hospital

    Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.